NEW YORK (GenomeWeb) – Seven Bridges and SolveBio said today that they have integrated their respective genomic data analysis platforms.
Seven Bridges' platform offers tools for analyzing millions of genomes in concert with other forms of biomedical data. The company's platform was one of three selected for the National Cancer Institute's Cancer Genomics Cloud Pilot initiative. Earlier this year, the NCI expanded its contract with the company to include the addition of new data sources and better integration with the institute's Genomic Data Commons. Seven Bridges also has a contract with the US Department of Veteran Affairs to develop a hybrid cloud for genome data analysis and a genotype-phenotype graph-analysis engine for the VA's Million Veteran Program. The company is also partnering with the Children's Hospital of Philadelphia to develop a shared environment for securely storing, sharing, and analyzing large volumes of genomic data from pediatric patients.
SolveBio has developed technology that enables customers in the pharmaceutical, biotechnology, and diagnostic industries to use multi-omics and clinical outcomes data for therapeutic and diagnostic development. The company's core technology allows it to index, harmonize, and link biomarker and variant data in real time and make it available to customers. The integration between the two companies makes it possible for joint customers to analyze and annotate large genomic datasets using Seven Bridges tools and customizable workflows and then push relevant findings to SolveBio for deep functional interpretation and assessment of clinical impact, the companies said.
Seven Bridges' customers can access SolveBio's knowledgebase and intelligence tools from Seven Bridges' public apps repository. According to the partners, researchers at the NCI are already using the integrated platforms to analyze data for the institute's cancer epidemiology and genetics research program. Researchers there are seeking to discover genetic and environmental determinants of cancer and new methods for preventing the disease.
Financial and other terms of the agreement were not disclosed.
In February, Seven Bridges raised $45 million in a Series A financing round led by Kryssen Capital that it is using the expand the number of national-scale projects that it can tackle.
For its part, SolveBio has raised $4.5M to date from Andreessen Horowitz, Max Levchin, Faridan Ventures, Nat Turner, and other investors. The company also has product integration agreements with companies such as DNAnexus, Ranomics, Amplion, and MedGenome.